Literature DB >> 15316248

Cancer incidence in multiple sclerosis: a 35-year follow-up.

Marja-Liisa Sumelahti1, Eero Pukkala, Matti Hakama.   

Abstract

The risk of cancer among multiple sclerosis (MS) patients was evaluated emphasising cancers with a potentially infectious aetiology. Cancer incidence was estimated among incident MS patients in 1964-1993 (n = 1,597) in Finland. The cohort was followed up for cancer incidence through the Finnish Cancer Registry until 1999. A total of 85 cancer cases were diagnosed showing a standardised incidence ratio (SIR) of 1.0 (95% CI 0.8-1.2) for all cancers. The risk (SIR) of haematological tumours was 1.1 and that of central nervous system (CNS) tumours 1.3. The small excess risk of haematological malignancies is consistent with infectious aetiology, whereas the association between MS and CNS tumours may be due to misclassification.

Entities:  

Mesh:

Year:  2004        PMID: 15316248     DOI: 10.1159/000079947

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  17 in total

Review 1.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

2.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

Review 3.  Small cell lung carcinoma presenting with acute disseminated encephalomyelitis.

Authors:  R Summerfield; A Al-Saleh; S E Robbins
Journal:  Br J Radiol       Date:  2010-03       Impact factor: 3.039

Review 4.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

5.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.

Authors:  Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen
Journal:  Blood       Date:  2008-02-08       Impact factor: 22.113

6.  Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.

Authors:  Dimitrios Papadopoulos; Panagiotis Gklinos; Giorgos Psarros; Konstantina Drellia; Eumorphia Maria Delicha; Tim Friede; Dimos D Mitsikostas; Richard S Nicholas
Journal:  J Neurol       Date:  2022-01-23       Impact factor: 4.849

7.  C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map.

Authors:  Anton G Kutikhin; Arseniy E Yuzhalin
Journal:  Cancer Manag Res       Date:  2012-02-24       Impact factor: 3.989

8.  Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.

Authors:  Gary Bloomgren; Bjørn Sperling; Kimberly Cushing; Madé Wenten
Journal:  Ther Clin Risk Manag       Date:  2012-06-20       Impact factor: 2.423

Review 9.  A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Stephen C Reingold; Gary Cutter
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 10.  A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Authors:  Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-26       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.